Corticosteroids Impair Remyelination in the Corpus Callosum of Cuprizone-Treated Mice

Journal of Neuroendocrinology

Volumn 23, Issue 7, 2011, Pages 601-611

  Clarner, T ^a   Parabucki, A ^b   Beyer, C ^a   Kipp, M ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Corpus callosum; Dexamethasone; Glucocorticoid; Myelin; Oligodendrocyte

Indexed keywords

CUPRIZONE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; PLATELET DERIVED GROWTH FACTOR AA; PROTEOLIPID PROTEIN; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL COUNT; CELL MATURATION; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; DRUG EFFECT; GENE EXPRESSION; IN VIVO STUDY; INFLAMMATORY CELL; MALE; MICROGLIA; MOUSE; NERVE CELL CULTURE; NERVE REGENERATION; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMYELINIZATION;

ADRENAL CORTEX HORMONES; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CHELATING AGENTS; CORPUS CALLOSUM; CUPRIZONE; DEMYELINATING DISEASES; DEXAMETHASONE; DRUG EVALUATION, PRECLINICAL; MALE; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; MYELIN SHEATH; NERVE REGENERATION; OLIGODENDROGLIA; RATS;

EID: 79959261966     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02140.x     Document Type: Article

References (71)

1. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005; 11: 425-432.
2. Baracskay KL, Duchala CS, Miller RH, Macklin WB, Trapp BD. Oligodendrogenesis is differentially regulated in gray and white matter of jimpy mice. J Neurosci Res 2002; 70: 645-654.
3. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7: 841-851.
4. Geurts JJ, Stys PK, Minagar A, Amor S, Zivadinov R. Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009; 282: 12-20.
5. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Bruck W, Lucchinetti C, Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-3172.
6. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-855.
7. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131: 1464-1477.
8. Smith EJ, Blakemore WF, McDonald WI. Central remyelination restores secure conduction. Nature 1979; 280: 395-396.
9. Halliday AM. Visual evoked potentials in demyelinating disease. Adv Neurol 1981; 31: 201-215.
10. Triarhou LC, Herndon RM. The effect of dexamethasone on L-alpha-lysophosphatidyl choline (lysolecithin)-induced demyelination of the rat spinal cord. Arch Neurol 1986; 43: 121-125.
11. Chari DM, Zhao C, Kotter MR, Blakemore WF, Franklin RJ. Corticosteroids delay remyelination of experimental demyelination in the rodent central nervous system. J Neurosci Res 2006; 83: 594-605.
12. Pavelko KD, van Engelen BG, Rodriguez M. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J Neurosci 1998; 18: 2498-2505.
13. Bohn MC, Howard E, Vielkind U, Krozowski Z. Glial cells express both mineralocorticoid and glucocorticoid receptors. J Steroid Biochem Mol Biol 1991; 40: 105-111.
14. Barres BA, Lazar MA, Raff MC. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 1994; 120: 1097-1108.
15. Holzknecht C, Rohl C. Effects of methylprednisolone and glatiramer acetate on nitric oxide formation of cytokine-stimulated cells from the rat oligodendroglial cell line OLN-93. Neuroimmunomodulation 2010; 17: 23-30.
16. Sun YY, Wang CY, Hsu MF, Juan SH, Chang CY, Chou CM, Yang LY, Hung KS, Xu J, Lee YH, Hsu CY. Glucocorticoid protection of oligodendrocytes against excitotoxin involving hypoxia-inducible factor-1alpha in a cell-type-specific manner. J Neurosci 2010; 30: 9621-9630.
17. Xu J, Chen S, Chen H, Xiao Q, Hsu CY, Michael D, Bao J. STAT5 mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J Neurosci 2009; 29: 2022-2026.
18. Joubert L, Foucault I, Sagot Y, Bernasconi L, Duval F, Alliod C, Frossard MJ, Pescini Gobert R, Curchod ML, Salvat C, Nichols A, Pouly S, Rommel C, Roach A, Hooft van Huijsduijnen R. Chemical inducers and transcriptional markers of oligodendrocyte differentiation. J Neurosci Res 2010; 88: 2546-2557.
19. Kumar S, Cole R, Chiappelli F, de Vellis J. Differential regulation of oligodendrocyte markers by glucocorticoids: post-transcriptional regulation of both proteolipid protein and myelin basic protein and transcriptional regulation of glycerol phosphate dehydrogenase. Proc Natl Acad Sci USA 1989; 86: 6807-6811.
20. Almazan G, Honegger P, Du Pasquier P, Matthieu JM. Dexamethasone stimulates the biochemical differentiation of fetal forebrain cells in reaggregating cultures. Dev Neurosci 1986; 8: 14-23.
21. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165-173.
22. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, Berente Z, Komoly S, Beyer C. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 2009; 57: 807-814.
23. Clarner T, Buschmann JP, Beyer C, Kipp M. Glial amyloid precursor protein expression is restricted to astrocytes in an experimental toxic model of multiple sclerosis. J Mol Neurosci 2010; 43: 268-274.
24. Groebe A, Clarner T, Baumgartner W, Dang J, Beyer C, Kipp M. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 2009; 8: 163-174.
25. Pott F, Gingele S, Clarner T, Dang J, Baumgartner W, Beyer C, Kipp M. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res 2009; 1305: 137-149.
26. Richter-Landsberg C, Vollgraf U. Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells. Exp Cell Res 1998; 244: 218-229.
27. Braun A, Dang J, Johann S, Beyer C, Kipp M. Selective regulation of growth factor expression in cultured cortical astrocytes by neuro-pathological toxins. Neurochem Int 2009; 55: 610-618.
28. Norkute A, Kipp M, Dang J, von Keyserlingk DG, Valanciute A, Beyer C. Early formation of a GFAP-positive cell population in the ventricular zone during chicken brain development. Cell Tiss Org 2010; 191: 57-65.
29. Kramer M, Dang J, Baertling F, Denecke B, Clarner T, Kirsch C, Beyer C, Kipp M. TTC staining of damaged brain areas after MCA occlusion in the rat does not constrict quantitative gene and protein analyses. J Neurosci Methods 2010; 187: 84-89.
30. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
31. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002; 53: 285-302.
32. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-1769.
33. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-1247.
34. de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10: 596-597.
35. Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008:CD006264.
36. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1961; 1: 127-129.
37. Bakker DA, Ludwin SK. Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 1987; 78: 125-137.
38. Kondo A, Nakano T, Suzuki K. Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res 1987; 425: 186-190.
39. Liu L, Belkadi A, Darnall L, Hu T, Drescher C, Cotleur AC, Padovani-Claudio D, He T, Choi K, Lane TE, Miller RH, Ransohoff RM. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci 2010; 13: 319-326.
40. Pringle N, Collarini EJ, Mosley MJ, Heldin CH, Westermark B, Richardson WD. PDGF A chain homodimers drive proliferation of bipotential (O-2A) glial progenitor cells in the developing rat optic nerve. EMBO J 1989; 8: 1049-1056.
41. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 1983; 303: 390-396.
42. Bogler O, Wren D, Barnett SC, Land H, Noble M. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci USA 1990; 87: 6368-6372.
43. McKinnon RD, Matsui T, Aranda M, Dubois-Dalcq M. A role for fibroblast growth factor in oligodendrocyte development. Ann NY Acad Sci 1991; 638: 378-386.
44. D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G. The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 1996; 13: 227-255.
45. Mason JL, Ye P, Suzuki K, D'Ercole AJ, Matsushima GK. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 2000; 20: 5703-5708.
46. Komoly S, Hudson LD, Webster HD, Bondy CA. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 1992; 89: 1894-1898.
47. Moore CS, Abdullah SL, Brown A, Arulpragasam A, Crocker SJ. How factors secreted from astrocytes impact myelin repair. J Neurosci Res 2011; 89: 13-21.
48. Chesik D, De Keyser J. Progesterone and dexamethasone differentially regulate the IGF-system in glial cells. Neurosci Lett 2010; 468: 178-182.
49. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009; 118: 723-736.
50. Blakemore WF. Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone. J Neurol Sci 1973; 20: 73-83.
51. Preston SL, McMorris FA. Adrenalectomy of rats results in hypomyelination of the central nervous system. J Neurochem 1984; 42: 262-267.
52. Gumbinas M, Oda M, Huttenlocher P. The effects of corticosteroids on myelination of the developing rat brain. Biol Neonate 1973; 22: 355-366.
53. Dunlop SA, Archer MA, Quinlivan JA, Beazley LD, Newnham JP. Repeated prenatal corticosteroids delay myelination in the ovine central nervous system. J Matern Fetal Med 1997; 6: 309-313.
54. Wei ZS, Hong MF, Su QX, Wang XH, Yu QY, Peng ZX, Zhang MX, Jie A, Wang R, Huang YQ. Super-high-dose methylprednisolone does not improve efficacy or induce glucocorticoid resistance in experimental allergic encephalomyelitis. Neuroimmunomodulation 2010; 18: 28-36.
55. Raschke C, Schmidt S, Schwab M, Jirikowski G. Effects of betamethasone treatment on central myelination in fetal sheep: an electron microscopical study. Anat Histol Embryol 2008; 37: 95-100.
56. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, Casaccia-Bonnefil P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008; 11: 1024-1034.
57. Krukowski K, Eddy J, Kosik KL, Konley T, Janusek LW, Mathews HL. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification. Brain Behav Immun 2011; 25: 239-249.
58. Hinkerohe D, Smikalla D, Schoebel A, Haghikia A, Zoidl G, Haase CG, Schlegel U, Faustmann PM. Dexamethasone prevents LPS-induced microglial activation and astroglial impairment in an experimental bacterial meningitis co-culture model. Brain Res 2010; 1329: 45-54.
59. Lavista Llanos S, Roldan A. Effect of dexamethasone on nitric oxide (NO.) production by cultured astrocytes. Biocell 1999; 23: 29-35.
60. Zhou Y, Ling EA, Dheen ST. Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 2007; 102: 667-678.
61. Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 2007; 33: 277-287.
62. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. Interleukin-1beta promotes repair of the CNS. J Neurosci 2001; 21: 7046-7052.
63. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116-1122.
64. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 2003; 23: 9824-9832.
65. Njenga MK, Murray PD, McGavern D, Lin X, Drescher KM, Rodriguez M. Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. J Neuropathol Exp Neurol 1999; 58: 78-91.
66. Biancotti JC, Kumar S, de Vellis J. Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem Res 2008; 33: 2615-2628.
67. Fernandez M, Giuliani A, Pirondi S, D'Intino G, Giardino L, Aloe L, Levi-Montalcini R, Calza L. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA 2004; 101: 16363-16368.
68. Franco PG, Silvestroff L, Soto EF, Pasquini JM. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol 2008; 212: 458-467.
69. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 2008; 28: 14189-14201.
70. Nicoloff JT, Fisher DA, Appleman MD Jr. The role of glucocorticoids in the regulation of thyroid function in man. J Clin Invest 1970; 49: 1922-1929.
71. Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest 1969; 48: 2096-2103.